Treatment Study for Patients with BRAF V600E Mutation Positive Craniopharyngioma
This phase II trial studies how well vemurafenib and cobimetinib work in treating patients with BRAF V600E mutation positive craniopharyngioma. Vemurafenib and cobimetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
In order to participate you must meet the following criteria:
- Have local diagnosis of papillary craniopharyngioma and have tissue slides available for submission to central pathology review.
- Have histologically proven papillary craniopharyngioma as documented by central pathology review with positive BRAF V600E mutation by IHC.
- Are at least 18 years of age.
This is a partial list of elgibility requirements.